In 2749 adults with type 2 diabetes and high cardiovascular risk, oral orforglipron was non-inferior to insulin glargine for MACE-4 over 2 years (4.2% vs 5.0%; HR 0.84, 95% CI 0.59-1.20). GI adverse events were more common (62% vs 14%).
RCTn = 2,749
Klein et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial